Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 4/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4517266 | 0.86 | FAAH (0.46) | CHRNB4CHRNA3ALDH1A1CHRNB2CHRNA4 | |
| SCHEMBL4535781 | 0.86 | ALDH1A1 (0.48) | CHRNB4CHRNA3NPSR1ALDH1A1CHRNB2 | |
| SCHEMBL8795523 | 0.84 | CHRNB4 (0.66) | CHRNB4CHRNA3DRD4CHRNB2CHRNA4 | |
| SCHEMBL8795514 | 0.84 | CHRNB4 (0.66) | CHRNB4CHRNA3DRD4CHRNB2CHRNA4 | |
| SCHEMBL4534956 | 0.82 | CHRNB4 (0.53) | CHRNB4CHRNA3ALDH1A1DRD4CHRNB2 | |
| SCHEMBL8792640 | 0.81 | CHRNB4 (0.61) | CHRNB4CHRNA3ALDH1A1DRD4CHRNB2 | |
| SCHEMBL5257833 | 0.80 | CHRNB4 (0.66) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL29007827 | 0.78 | CHRNB4 (0.41) | CHRNB4CHRNA3MEN1KMT2A | |
| SCHEMBL4855409 | 0.78 | DRD2 (0.48) | CHRNB4CHRNA3ALDH1A1DRD4MEN1 | |
| SCHEMBL8791874 | 0.78 | DRD4 (0.52) | CHRNB4CHRNA3NPSR1L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | PLE PATRICK | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | AQP3, AQP1, F12 | CHRNB4 3510/4885CHRNA3 1335/4885NPSR1 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.